Feasibility Testing of the "Face-Forward-Web" Program for Chronic Orofacial Pain
Launched by MASSACHUSETTS GENERAL HOSPITAL · Dec 23, 2024
Trial Information
Current as of July 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is testing a new online program called "Face-Forward-Web," designed to help adults who experience chronic orofacial pain, which is pain affecting the face and jaw area. The main goal of this study is to see how well the program works and how acceptable it is for patients who might use it. The researchers will gather feedback from up to 20 participants through interviews after they complete the program, helping them understand if any changes are needed before moving on to larger studies.
To participate in this trial, you need to be at least 18 years old, able to read and understand English, and have been experiencing non-cancer-related facial pain for at least three months. Participants should also have a pain level of 4 or higher on a scale from 0 to 10. It's important that you own a device with internet access, as the program is web-based. However, if you've been practicing mindfulness for more than 45 minutes a week recently or have received certain therapies in the past three months, you may not be eligible. The trial is not currently recruiting participants, but it aims to refine the program based on the feedback received and prepare for future studies.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥18
- • 2. English fluency and literacy
- • 3. Nonmalignant chronic (\>3 months) orofacial pain
- • 4. Ability and willingness to participate in the Face-Forward web-platform intervention
- • 5. Free of concurrent psychotropic medication 2 week prior to participation OR stable psychotropic medication dose and type for ≥ 6 weeks
- • 6. Pain score ≥4/10 on the Numerical Rating Scale
- • 7. Owns (or has easy access to) a device with internet access
- Exclusion Criteria:
- • 1. Practice of mindfulness \> 45 minutes/week in the past 3 months
- • 2. Participation in mind-body or cognitive-behavioral therapy in the past 3 months
- • 3. Severe untreated mental health disorder (e.g., psychosis)
- • 4. Active suicidal ideation with plan or intent
- • 5. Pregnancy
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported